share_log

Canaccord Genuity Group Begins Coverage on GreenLight Biosciences (NASDAQ:GRNA)

Canaccord Genuity Group Begins Coverage on GreenLight Biosciences (NASDAQ:GRNA)

Canaccord Genuity Group 开始报道绿光生物科学（纳斯达克股票代码：GRNA）
kopsource ·  2022/12/11 04:42

Canaccord Genuity Group began coverage on shares of GreenLight Biosciences (NASDAQ:GRNA – Get Rating) in a research report sent to investors on Thursday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $4.00 target price on the stock.

Canaccord Genuity Group 开始报道以下公司的股票 GreenLight Biosciences（纳斯达克：GRNA — 获取评级 在周四发送给投资者的研究报告中，MarketBeat Ratings报道。该经纪公司对该股发布了买入评级和4.00美元的目标价。

Separately, Credit Suisse Group began coverage on GreenLight Biosciences in a research report on Friday, October 14th. They set an outperform rating and a $5.50 price target on the stock.

另外，瑞士信贷集团在10月14日星期五的一份研究报告中开始报道GreenLight Biosciences。他们为该股设定了跑赢大盘的评级和5.50美元的目标股价。

Get
获取
GreenLight Biosciences
绿光生物科学
alerts:
警报：

GreenLight Biosciences Trading Up 3.6 %

绿光生物科学交易上涨3.6％

Shares of GreenLight Biosciences stock opened at $1.14 on Thursday. The business's fifty day moving average price is $1.76 and its two-hundred day moving average price is $2.75. The company has a quick ratio of 3.37, a current ratio of 3.37 and a debt-to-equity ratio of 0.20. GreenLight Biosciences has a 1-year low of $1.05 and a 1-year high of $15.80.

周四，GreenLight Biosciences股票开盘价为1.14美元。该公司的五十天移动平均价格为1.76美元，其两百天移动平均线价格为2.75美元。该公司的速动比率为3.37，流动比率为3.37，债务与权益比率为0.20。GreenLight Biosciences创下了1.05美元的1年低点和15.80美元的1年高点。

Hedge Funds Weigh In On GreenLight Biosciences

对冲基金权衡绿光生物科学

A number of hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp grew its holdings in shares of GreenLight Biosciences by 340.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 213,329 shares of the company's stock worth $495,000 after acquiring an additional 164,893 shares during the last quarter. California State Teachers Retirement System grew its holdings in shares of GreenLight Biosciences by 47.2% in the 3rd quarter. California State Teachers Retirement System now owns 71,001 shares of the company's stock worth $165,000 after acquiring an additional 22,773 shares during the last quarter. Baird Financial Group Inc. acquired a new position in shares of GreenLight Biosciences in the 3rd quarter worth $6,628,000. State Street Corp grew its holdings in shares of GreenLight Biosciences by 108.2% in the 3rd quarter. State Street Corp now owns 811,721 shares of the company's stock worth $1,883,000 after acquiring an additional 421,797 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of GreenLight Biosciences by 29.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,205,436 shares of the company's stock worth $2,797,000 after acquiring an additional 274,020 shares during the last quarter. 23.94% of the stock is currently owned by institutional investors and hedge funds.
一些对冲基金最近修改了该股的持有量。纽约银行梅隆公司在第三季度将其持有的GreenLight Biosciences股票增加了340.4％。纽约银行梅隆公司在上个季度又收购了164,893股股票后，现在拥有该公司213,329股股票，价值49.5万美元。加利福尼亚州教师退休系统在第三季度将其持有的GreenLight Biosciences股票增加了47.2％。加利福尼亚州教师退休系统在上个季度又收购了22,773股股票后，现在拥有该公司71,001股股票，价值16.5万美元。贝尔德金融集团公司在第三季度收购了价值662.8万美元的GreenLight Biosciences股票的新头寸。State Street Corp在第三季度将其持有的GreenLight Biosciences股票增加了108.2％。State Street Corp在上个季度又收购了421,797股股票后，现在拥有该公司811,721股股票，价值18.83万美元。最后，Vanguard Group Inc.在第三季度将其持有的GreenLight Biosciences股票增加了29.4％。Vanguard Group Inc.在上个季度又收购了274,020股股票后，现在拥有该公司1,205,436股股票，价值279.7万美元。23.94％的股票目前由机构投资者和对冲基金持有。

GreenLight Biosciences Company Profile

GreenLight 生物科学公司简介

(Get Rating)

（获取评分）

GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.

生物技术公司GreenLight Biosciences Holdings生产和销售用于人类健康和农业应用的核糖核酸（RNA）产品。其用于人类健康的产品包括mRNA疫苗和疗法；以及用于保护蜜蜂和农作物的农用RNA产品。该公司成立于2008年，总部位于马萨诸塞州梅德福。

Featured Stories

精选故事

  • Get a free copy of the StockNews.com research report on GreenLight Biosciences (GRNA)
  • MarketBeat: Week in Review 12/05 – 12/09
  • There Is Fundamental Value In Broadcom, And It Yields 3.35%
  • Costco vs Amazon: an end of the year showdown
  • Discount Retailers Could Make Good Bargain Stocks
  • Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
  • 免费获取 StockNews.com 关于 GreenLight Biosciences (GRNA) 的研究报告
  • MarketBeat：本周回顾 12 月 12 日 — 2009 年 12 月
  • 博通具有基本价值，其收益率为3.35％
  • 好市多与亚马逊：年终对决
  • 折扣零售商可以赚到不错的廉价股票
  • 辉瑞、强生能否继续跑赢该指数？

Receive News & Ratings for GreenLight Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GreenLight Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

接收《绿光生物科学日报》的新闻和评级 -在下面输入您的电子邮件地址，即可通过MarketBeat.com的免费每日电子邮件时事通讯接收GreenLight Biosciences及相关公司的最新新闻和分析师评级的简明每日摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发